Vaccination response
Conditions
Brief summary
a. Renal function and proteinuria. (creatinin and CKD-EPI; urine spot protein/ creatinine) b. Patient survival. c. Rejection episodes. d. Infectious complications: opportunistic infections, use of antibiotics. e. Malignancy o Skin (diagnosed via routine dermatology check-up) o Non-skin.
Detailed description
Determination of donor-specific antibodies using Luminex single-antigen beads 4, 6 and 10 years after transplantation., Quantification of pneumococcal vaccination response 3 and 5 years after pneumococcal vaccination (year 4 and 6 after kidney transplantation) with the 23-serotype polyvalent pneumococcal vaccine; and 3 weeks and one year after booster vaccination 5 years after the initial vaccination.
Interventions
DRUGPneumovax 23
DRUGoplossing voor injectie in een voorgevulde spuit Pneumokokkenpolysacharidevaccin
Sponsors
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a. Renal function and proteinuria. (creatinin and CKD-EPI; urine spot protein/ creatinine) b. Patient survival. c. Rejection episodes. d. Infectious complications: opportunistic infections, use of antibiotics. e. Malignancy o Skin (diagnosed via routine dermatology check-up) o Non-skin. | — |
Secondary
| Measure | Time frame |
|---|---|
| Determination of donor-specific antibodies using Luminex single-antigen beads 4, 6 and 10 years after transplantation., Quantification of pneumococcal vaccination response 3 and 5 years after pneumococcal vaccination (year 4 and 6 after kidney transplantation) with the 23-serotype polyvalent pneumococcal vaccine; and 3 weeks and one year after booster vaccination 5 years after the initial vaccination. | — |
Countries
Netherlands
Outcome results
None listed